Prof. Dr. Beat Thürlimann
Prevention of docetaxel- or paclitaxel-associated taste alterations in cancer patients with oral glutamine: a randomized, placebo-controlled, double-blind study
Strasser F, Demmer-Steingruber R, Böhme C, Schmitz S, Thürlimann B, Cerny T, Gillessen Sommer S. Prevention of docetaxel- or paclitaxel-associated taste alterations in cancer patients with oral glutamine: a randomized, placebo-controlled, double-blind study. The Oncologist 2008; 13:337-46.
Mar 1, 2008Prevention of docetaxel- or paclitaxel-associated taste alterations in cancer patients with oral glutamine: a randomized, placebo-controlled, double-blind study
Mar 1, 2008The Oncologist 2008; 13:337-46
Strasser Florian, Demmer-Steingruber Ruth, Böhme Christel, Schmitz Shu-Fang Hsu, Thürlimann Beat, Cerny Thomas, Gillessen Sommer Silke
Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel
Aapro M, Saad F, Rizzoli R, Paterson A, Monnier A, Lipton A, Jonat W, Hortobagyi G, Hadji P, Gralow J, Gnant M, Dirix L, Crinò L, Costa L, Colomer R, Coleman R, Body J, Abrahamsson P, Thürlimann B. Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel. Ann Oncol 2008; 19:420-32.
Mar 1, 2008Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel
Mar 1, 2008Ann Oncol 2008; 19:420-32
Aapro M, Saad F, Rizzoli R, Paterson A H G, Monnier A, Lipton A, Jonat W, Hortobagyi G N, Hadji P, Gralow J, Gnant M, Dirix L, Crinò L, Costa L, Colomer R, Coleman R E, Body J J, Abrahamsson P A, Thürlimann Beat
Safety, tolerability and pharmacokinetics of intravenous ghrelin for cancer-related anorexia/cachexia: a randomised, placebo-controlled, double-blind, double-crossover study
Strasser F, Cerny T, Von Moss R, Brändle M, Holst B, Kaufmann K, Tschöp M, Büche D, Thürlimann B, Maeder M, Lutz T, Demmer-Steingruber R. Safety, tolerability and pharmacokinetics of intravenous ghrelin for cancer-related anorexia/cachexia: a randomised, placebo-controlled, double-blind, double-crossover study. BJC 2008; 98:300-8.
Jan 29, 2008Safety, tolerability and pharmacokinetics of intravenous ghrelin for cancer-related anorexia/cachexia: a randomised, placebo-controlled, double-blind, double-crossover study
Jan 29, 2008BJC 2008; 98:300-8
Strasser Florian, Cerny Thomas, Von Moss Roger, Brändle Michael, Holst B, Kaufmann K, Tschöp M, Büche Daniel, Thürlimann Beat, Maeder Micha, Lutz T A, Demmer-Steingruber Ruth
Quality of life and quality-adjusted survival (Q-TWiST) in patients receiving dose-intensive or standard dose chemotherapy for high-risk primary breast cancer
Bernhard J, Coates A, Goldhirsch A, Price K, Castiglione-Gertsch M, Gelber R, Colleoni M, Green M, Thürlimann B, Yeo W, Aebi S, Forbes J, Hürny C, Basser R, Martinelli G, Zhang J, Zahrieh D, International Breast Cancer Study Group. Quality of life and quality-adjusted survival (Q-TWiST) in patients receiving dose-intensive or standard dose chemotherapy for high-risk primary breast cancer. BJC 2008; 98:25-33.
Jan 15, 2008Quality of life and quality-adjusted survival (Q-TWiST) in patients receiving dose-intensive or standard dose chemotherapy for high-risk primary breast cancer
Jan 15, 2008BJC 2008; 98:25-33
Bernhard J, Coates A S, Goldhirsch A, Price K N, Castiglione-Gertsch M, Gelber R D, Colleoni M, Green M D, Thürlimann Beat, Yeo W, Aebi S, Forbes J F, Hürny C, Basser R, Martinelli G, Zhang J J, Zahrieh D, International Breast Cancer Study Group
Adjuvant letrozole versus tamoxifen according to centrally-assessed ERBB2 status for postmenopausal women with endocrine-responsive early breast cancer: supplementary results from the BIG 1-98 randomised trial
Rasmussen B, Altermatt H, Gelber R, Castiglione-Gertsch M, Goldhirsch A, Gusterson B, Thürlimann B, Coates A, Viale G, Braye S, Lacroix-Triki M, Regan M, Lykkesfeldt A, Dell'Orto P, Del Curto B, Henriksen K, Mastropasqua M, Price K, Méry E, BIG 1-98 Collaborative and International Breast Cancer Study Groups. Adjuvant letrozole versus tamoxifen according to centrally-assessed ERBB2 status for postmenopausal women with endocrine-responsive early breast cancer: supplementary results from the BIG 1-98 randomised trial. The Lancet 2008; 9:23-8.
Jan 1, 2008Adjuvant letrozole versus tamoxifen according to centrally-assessed ERBB2 status for postmenopausal women with endocrine-responsive early breast cancer: supplementary results from the BIG 1-98 randomised trial
Jan 1, 2008The Lancet 2008; 9:23-8
Rasmussen Birgitte B, Altermatt Hans J, Gelber Richard D, Castiglione-Gertsch Monica, Goldhirsch Aron, Gusterson Barry A, Thürlimann Beat, Coates Alan S, Viale Giuseppe, Braye Stephen, Lacroix-Triki Magali, Regan Meredith M, Lykkesfeldt Anne E, Dell'Orto Patrizia, Del Curto Barbara, Henriksen Katrine L, Mastropasqua Mauro G, Price Karen N, Méry Eliane, BIG 1-98 Collaborative and International Breast Cancer Study Groups
Cardiovascular adverse events during adjuvant endocrine therapy for early breast cancer using letrozole or tamoxifen: safety analysis of BIG 1-98 trial
Mouridsen H, Price K, Smith I, Colleoni M, Gelber R, Paridaens R, Forbes J, Mauriac L, Thürlimann B, Sun Z, Castiglione-Gertsch M, Rabaglio M, Coates A, Keshaviah A, Goldhirsch A. Cardiovascular adverse events during adjuvant endocrine therapy for early breast cancer using letrozole or tamoxifen: safety analysis of BIG 1-98 trial. JCO 2007; 25:5715-22.
Dec 20, 2007Cardiovascular adverse events during adjuvant endocrine therapy for early breast cancer using letrozole or tamoxifen: safety analysis of BIG 1-98 trial
Dec 20, 2007JCO 2007; 25:5715-22
Mouridsen Henning, Price Karen N, Smith Ian, Colleoni Marco, Gelber Richard D, Paridaens Robert, Forbes John F, Mauriac Louis, Thürlimann Beat, Sun Zhuoxin, Castiglione-Gertsch Monica, Rabaglio Manuela, Coates Alan S, Keshaviah Aparna, Goldhirsch Aron
Endocrine symptom assessment in women with breast cancer: what a simple "yes" means
Ribi K, Bernhard J, Rufibach K, Thürlimann B, von Moos R, Ruhstaller T, Glaus A, Böhme C. Endocrine symptom assessment in women with breast cancer: what a simple "yes" means. JSCC 2007; 15:1349-56.
Dec 1, 2007Endocrine symptom assessment in women with breast cancer: what a simple "yes" means
Dec 1, 2007JSCC 2007; 15:1349-56
Ribi K, Bernhard J, Rufibach K, Thürlimann Beat, von Moos R, Ruhstaller Thomas, Glaus A, Böhme C
Is surgery still part of local therapy in patients with locally advanced esophageal carcinoma?
Ruhstaller T, Thürlimann B, Köberle D, von Moos R. Is surgery still part of local therapy in patients with locally advanced esophageal carcinoma?. JCO 2007; 25:4025-6; author reply 4026-7.
Sep 1, 2007Is surgery still part of local therapy in patients with locally advanced esophageal carcinoma?
Sep 1, 2007JCO 2007; 25:4025-6; author reply 4026-7
Ruhstaller Thomas, Thürlimann Beat, Köberle Dieter, von Moos Roger
Reducing the risk of early recurrence in hormone-responsive breast cancer
Thürlimann B. Reducing the risk of early recurrence in hormone-responsive breast cancer. Ann Oncol 2007; 18 Suppl 8:viii8-17.
Sep 1, 2007Reducing the risk of early recurrence in hormone-responsive breast cancer
Sep 1, 2007Ann Oncol 2007; 18 Suppl 8:viii8-17
Thürlimann Beat
Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal early breast cancer: BIG 1-98
Viale G, Gusterson B, Goldhirsch A, Price K, Castiglione-Gertsch M, Gelber R, Thürlimann B, Öhlschlegel C, Braye S, Orosz Z, Neven P, Raffoul J, Rasmussen B, Dell'Orto P, Mastropasqua M, Maiorano E, Regan M, Coates A. Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal early breast cancer: BIG 1-98. J Clin Oncol 2007; 25:3846-52.
Aug 6, 2007Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal early breast cancer: BIG 1-98
Aug 6, 2007J Clin Oncol 2007; 25:3846-52
Viale Giuseppe, Gusterson Barry A, Goldhirsch Aron, Price Karen N, Castiglione-Gertsch Monica, Gelber Richard D, Thürlimann Beat, Öhlschlegel Christian, Braye Stephen, Orosz Zsolt, Neven Patrick, Raffoul Johnny, Rasmussen Birgitte Bruun, Dell'Orto Patrizia, Mastropasqua Mauro G, Maiorano Eugenio, Regan Meredith M, Coates Alan S
Therapeutic impact of 2-[fluorine-18]fluoro-2-deoxy-D-glucose positron emission tomography in the pre- and postoperative staging of patients with clinically intermediate or high-risk breast cancer
Klaeser B, Wiederkehr O, Köberle D, Mueller A, Bubeck B, Thürlimann B. Therapeutic impact of 2-[fluorine-18]fluoro-2-deoxy-D-glucose positron emission tomography in the pre- and postoperative staging of patients with clinically intermediate or high-risk breast cancer. Ann Oncol 2007; 18:1329-34.
Aug 1, 2007Therapeutic impact of 2-[fluorine-18]fluoro-2-deoxy-D-glucose positron emission tomography in the pre- and postoperative staging of patients with clinically intermediate or high-risk breast cancer
Aug 1, 2007Ann Oncol 2007; 18:1329-34
Klaeser B, Wiederkehr O, Köberle Dieter, Mueller A, Bubeck B, Thürlimann Beat
Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007
Goldhirsch A, Wood W, Gelber R, Coates A, Thürlimann B, Senn H, 10th St. Gallen conference. Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007. Ann Oncol 2007; 18:1133-44.
Jul 1, 2007Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007
Jul 1, 2007Ann Oncol 2007; 18:1133-44
Goldhirsch A, Wood W C, Gelber R D, Coates A S, Thürlimann Beat, Senn H-J, 10th St. Gallen conference
Combining chemotherapy and low-molecular-weight heparin for the treatment of advanced breast cancer: results on clinical response, transforming growth factor-beta 1 and fibrin monomer in a phase II study
Seeholzer N, Thürlimann B, Köberle D, Hess D, Korte W. Combining chemotherapy and low-molecular-weight heparin for the treatment of advanced breast cancer: results on clinical response, transforming growth factor-beta 1 and fibrin monomer in a phase II study. Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis 2007; 18:415-23.
Jul 1, 2007Combining chemotherapy and low-molecular-weight heparin for the treatment of advanced breast cancer: results on clinical response, transforming growth factor-beta 1 and fibrin monomer in a phase II study
Jul 1, 2007Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis 2007; 18:415-23
Seeholzer Niels, Thürlimann Beat, Köberle Dieter, Hess Dagmar, Korte Wolfgang
The role of the number of uninvolved lymph nodes in predicting locoregional recurrence in breast cancer
Karlsson P, Goldhirsch A, Gelber R, Forbes J, Crivellari D, Thürlimann B, Fey M, Holmberg S, Collins J, Lindtner J, Murray E, Gusterson B, Castiglione-Gertsch M, Coates A, Price K, Cole B, Wallgren A. The role of the number of uninvolved lymph nodes in predicting locoregional recurrence in breast cancer. JCO 2007; 25:2019-26.
May 20, 2007The role of the number of uninvolved lymph nodes in predicting locoregional recurrence in breast cancer
May 20, 2007JCO 2007; 25:2019-26
Karlsson Per, Goldhirsch Aron, Gelber Richard D, Forbes John F, Crivellari Diana, Thürlimann Beat, Fey Martin F, Holmberg Stig B, Collins John P, Lindtner Jurij, Murray Elizabeth, Gusterson Barry A, Castiglione-Gertsch Monica, Coates Alan S, Price Karen N, Cole Bernard F, Wallgren Arne
Predictors of early relapse in postmenopausal women with hormone receptor-positive breast cancer in the BIG 1-98 trial
Mauriac L, Castiglione-Gertsch M, Price K, Coates A, Smith I, Viale G, Rabaglio M, Zabaznyi N, Goldhirsch A, BIG 1-98 Collaborative Group, Gelber R, Nogaret J, Keshaviah A, Debled M, Mouridsen H, Forbes J, Thürlimann B, Paridaens R, Monnier A, Láng I, Wardley A, International Breast Cancer Study Group. Predictors of early relapse in postmenopausal women with hormone receptor-positive breast cancer in the BIG 1-98 trial. Ann Oncol 2007; 18:859-67.
May 1, 2007Predictors of early relapse in postmenopausal women with hormone receptor-positive breast cancer in the BIG 1-98 trial
May 1, 2007Ann Oncol 2007; 18:859-67
Mauriac L, Castiglione-Gertsch M, Price K N, Coates A S, Smith I, Viale G, Rabaglio M, Zabaznyi N, Goldhirsch A, BIG 1-98 Collaborative Group, Gelber R D, Nogaret J-M, Keshaviah A, Debled M, Mouridsen H, Forbes J F, Thürlimann Beat, Paridaens R, Monnier A, Láng I, Wardley A, International Breast Cancer Study Group
CA15-3 and alkaline phosphatase as predictors for breast cancer recurrence: a combined analysis of seven International Breast Cancer Study Group trials
Keshaviah A, Coates A, Gelber R, Castiglione Gertsch M, Simoncini E, Pagani O, Price K, Aebi S, Mendiola C, Thürlimann B, Colleoni M, Collins J, Crivellari D, Lindtner J, Rotmensz N, Dellapasqua S, Goldhirsch A. CA15-3 and alkaline phosphatase as predictors for breast cancer recurrence: a combined analysis of seven International Breast Cancer Study Group trials. Ann Oncol 2007; 18:701-8.
Apr 1, 2007CA15-3 and alkaline phosphatase as predictors for breast cancer recurrence: a combined analysis of seven International Breast Cancer Study Group trials
Apr 1, 2007Ann Oncol 2007; 18:701-8
Keshaviah A, Coates A S, Gelber R D, Castiglione Gertsch M, Simoncini E, Pagani O, Price K N, Aebi S, Mendiola C, Thürlimann Beat, Colleoni M, Collins J, Crivellari D, Lindtner J, Rotmensz N, Dellapasqua S, Goldhirsch A
Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98
Coates A, Del Mastro L, Smith I, Chirgwin J, Nogaret J, Pienkowski T, Wardley A, Jakobsen E, Price K, Láng I, Colleoni M, Keshaviah A, Thürlimann B, Mouridsen H, Mauriac L, Forbes J, Paridaens R, Castiglione-Gertsch M, Gelber R, Goldhirsch A. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98. JCO 2007; 25:486-92.
Feb 10, 2007Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98
Feb 10, 2007JCO 2007; 25:486-92
Coates Alan S, Del Mastro Lucia, Smith Ian, Chirgwin Jacquie, Nogaret Jean-Marie, Pienkowski Tadeusz, Wardley Andrew, Jakobsen Erik H, Price Karen N, Láng István, Colleoni Marco, Keshaviah Aparna, Thürlimann Beat, Mouridsen Henning, Mauriac Louis, Forbes John F, Paridaens Robert, Castiglione-Gertsch Monica, Gelber Richard D, Goldhirsch Aron
Adjuvant chemotherapy followed by goserelin compared with either modality alone: the impact on amenorrhea, hot flashes, and quality of life in premenopausal patients--the International Breast Cancer Study Group Trial VIII
Bernhard J, Coates A, Goldhirsch A, Price K, Thürlimann B, Aebi S, Collins J, Murray E, Forbes J, Gelber R, Hürny C, Castiglione-Gertsch M, Zahrieh D, International Breast Cancer Study Group Trial VIII. Adjuvant chemotherapy followed by goserelin compared with either modality alone: the impact on amenorrhea, hot flashes, and quality of life in premenopausal patients--the International Breast Cancer Study Group Trial VIII. JCO 2007; 25:263-70.
Jan 20, 2007Adjuvant chemotherapy followed by goserelin compared with either modality alone: the impact on amenorrhea, hot flashes, and quality of life in premenopausal patients--the International Breast Cancer Study Group Trial VIII
Jan 20, 2007JCO 2007; 25:263-70
Bernhard Jürg, Coates Alan S, Goldhirsch Aron, Price Karen N, Thürlimann Beat, Aebi Stefan, Collins John, Murray Elizabeth, Forbes John F, Gelber Richard D, Hürny Christoph, Castiglione-Gertsch Monica, Zahrieh David, International Breast Cancer Study Group Trial VIII
Pegylated liposomal doxorubicin (caelyx) in metastatic breast cancer: a community-based observation study
Salzberg M, Thürlimann B, Hasler U, Delmore G, von Rohr A, Thurlimann A, Ruhstaller T, Stopatschinskaja S, von Moos R. Pegylated liposomal doxorubicin (caelyx) in metastatic breast cancer: a community-based observation study. Oncology 2007; 72:147-51.
Jan 1, 2007Pegylated liposomal doxorubicin (caelyx) in metastatic breast cancer: a community-based observation study
Jan 1, 2007Oncology 2007; 72:147-51
Salzberg Marc, Thürlimann Beat, Hasler Ursula, Delmore Geoffrey, von Rohr Albert, Thurlimann Annatina, Ruhstaller Thomas, Stopatschinskaja Shanna, von Moos Roger
Capecitabine and vinorelbine as first-line treatment in elderly patients (> or =65 years) with metastatic breast cancer. A phase II trial (SAKK 25/99)
Hess D, Ribi K, Ballabeni P, Schuller J, Rauch D, Rochlitz C, Mattmann S, Schonenberger A, Pagani O, Thürlimann B, Köberle D, Swiss Group for Clinical Cancer Research. Capecitabine and vinorelbine as first-line treatment in elderly patients (> or =65 years) with metastatic breast cancer. A phase II trial (SAKK 25/99). Oncology 2007; 73:228-37.
Jan 1, 2007Capecitabine and vinorelbine as first-line treatment in elderly patients (> or =65 years) with metastatic breast cancer. A phase II trial (SAKK 25/99)
Jan 1, 2007Oncology 2007; 73:228-37
Hess Dagmar, Ribi K, Ballabeni P, Schuller J C, Rauch D, Rochlitz C, Mattmann S, Schonenberger A, Pagani O, Thürlimann Beat, Köberle Dieter, Swiss Group for Clinical Cancer Research